Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
| ▸ | CTSG | P08311 | 1/20 | 0.34 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.34 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.34 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6534023 | 1.00 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2ELANECTSGTPSAB1 | |
| SCHEMBL6534024 | 1.00 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2ELANECTSGTPSAB1 | |
| SCHEMBL8301934 | 0.87 | SMN1; SMN2 (0.34) | HSD17B10SMN1; SMN2ELANECTSGHPGD | |
| SCHEMBL22968674 | 0.87 | SMN1; SMN2 (0.34) | HSD17B10SMN1; SMN2ELANECTSGHPGD | |
| SCHEMBL21366880 | 0.87 | SMN1; SMN2 (0.34) | HSD17B10SMN1; SMN2ELANECTSGHPGD | |
| SCHEMBL14899618 | 0.83 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2TPSAB1TPSD1TPSG1 | |
| SCHEMBL6924290 | 0.83 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2TPSAB1TPSD1TPSG1 | |
| SCHEMBL8344115 | 0.83 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2TPSAB1TPSD1TPSG1 | |
| SCHEMBL30591294 | 0.83 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2TPSAB1TPSD1TPSG1 | |
| SCHEMBL6924292 | 0.83 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2TPSAB1TPSD1TPSG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CYP11B1, HSD11B1, CYP11B2 | HSD17B10 26/4885SMN1; SMN2 1634/4885ELANE 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.